A Phase 3 interventional study of Haemophilus influenzae type b and meningococcal serogroup C (vaccine) and Priorix™ in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 7 sites in Australia. Open to participants aged 12 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-24.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 42nd largest by enrollment of the 80 interventional ones that give a count, is one of 14 that started in 2006, is one of 48 in phase 3, and was the 27th registered.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
Browse Haemophilus Infections studies →None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →
Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 12 Months to 18 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 14 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 433 is close to the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Median enrollment 445 across the 80 interventional studies, 270 across the 2 observational. Of the 81 that completed or were terminated, 55 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.
In the extension phase, at Years 1, 2, 3, 4 \& 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
This multicenter study is open and has 2 treatment groups with Hiberix™ + a commercially available MenC vaccine as active controls. Priorix™ is given concomitantly in both groups. In the primary phase, two blood samples are taken from all subjects for immunogenicity analyses: before and one month after vaccination. In the extension phase, at Year 1, 2, 3, 4 \& 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary phase:
Long-term persistence phase:
Exclusion Criteria:
For the primary vaccination phase:
Additional exclusion criteria for the long-term persistence phase: to be checked each year.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
Biological: Priorix™ · Biological: Hiberix™ · Biological: Meningitec™
Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine) · Biological: Priorix™
One intramuscular dose at 12-18 months of age
Also known as: Hib-MenC, Menitorix™
One subcutaneous dose at 12-18 months of age
One intramuscular dose at 12-18 months of age.
One intramuscular dose at 12-18 months of age
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.
Time frame: 1 month after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer
rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.
Time frame: 1 month after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers. Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Time frame: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Time frame: 5 years after vaccination
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Time frame: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Time frame: 5 years after vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
Time frame: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
Time frame: 5 years after vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Concentrations are given as Geometric Mean Concentrations (GMCs).
Time frame: Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Concentrations are given as Geometric Mean Concentrations (GMCs).
Time frame: 5 years after vaccination
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values
Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.
Time frame: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Anti-polysaccharide C (Anti-PSC) Antibody Concentrations
Concentrations given as Geometric Mean Concentrations (GMCs).
Time frame: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Number of Subjects Reporting Solicited Local and General Symptoms
Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.
Time frame: Within 4 days (Day 0 -Day 3) after vaccination
Number of Subjects Reporting Unsolicited Symptoms
Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Time frame: Within 31 days (Day 0 - Day 30) after vaccination
Number of Subjects Reporting Serious Adverse Events (SAEs)
A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.
Time frame: Throughout the entire study period (up to year 5)
| Milestone | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Started | 324 | 109 |
| Completed | 320 | 108 |
| Not completed | 4 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Milestone | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Started | 295 | 100 |
| Completed | 295 | 100 |
| Not completed | 0 | 0 |
| Milestone | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Started | 270 | 92 |
| Completed | 270 | 92 |
| Not completed | 0 | 0 |
| Milestone | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Started | 256 | 89 |
| Completed | 256 | 89 |
| Not completed | 0 | 0 |
| Milestone | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Started | 228 | 80 |
| Completed | 228 | 80 |
| Not completed | 0 | 0 |
| Milestone | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Started | 217 | 78 |
| Completed | 217 | 78 |
| Not completed | 0 | 0 |
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) | 292 | 100 |
rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer | 280 | 98 |
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers. Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| ≥ 1:8 [Prior to vaccination] (N=255, 83) | 37 | 7 |
| ≥ 1:8 [1 year after vaccination] (N=249, 89) | 216 | 68 |
| ≥ 1:8 [2 years after vaccination] (N= 235, 86) | 164 | 52 |
| ≥ 1:8 [3 years after vaccination] (N= 226, 77) | 145 | 41 |
| ≥ 1:8 [4 years after vaccination] (N= 208, 73) | 26 | 9 |
| ≥ 1:128 [Prior to vaccination] (N=255, 83) | 15 | 3 |
| ≥ 1:128 [1 month after vaccination] (N=281, 98) | 247 | 89 |
| ≥ 1:128 [1 year after vaccination] (N=249, 89) | 117 | 37 |
| ≥ 1:128 [2 years after vaccination] (N= 235, 86) | 76 | 26 |
| ≥ 1:128 [3 years after vaccination] (N= 226, 77) | 58 | 22 |
| ≥ 1:128 [4 years after vaccination] (N= 208, 73) | 7 | 4 |
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| ≥ 1:8 [5 years after vaccination] | 37 | 17 |
| ≥ 1:128 [5 years after vaccination ] | 12 | 7 |
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
| Titer | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Prior to vaccination (N= 255; 83) | 6.3 (5.5 to 7.3) | 5.5 (4.3 to 7.2) |
| 1 month after vaccination (N= 281; 98) | 482.8 (420.7 to 554.2) | 621.0 (480.3 to 802.9) |
| 1 year after vaccination (N= 249; 89) | 91.7 (75.6 to 111.3) | 63.8 (43.3 to 94.1) |
| 2 years after vaccination (N= 235; 86) | 39.3 (31.3 to 49.3) | 30.6 (20.1 to 46.7) |
| 3 years after vaccination (N= 226; 77) | 29.8 (23.6 to 37.6) | 21.8 (14.2 to 33.5) |
| 4 years after vaccination (N=208;73) | 5.3 (4.7 to 6.0) | 6.0 (4.5 to 8.0) |
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
| Titer | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers | 6.6 (5.6 to 7.8) | 8.5 (5.9 to 12.3) |
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| ≥ 0.15 µg/mL [Prior to vaccination] (N=285,98) | 219 | 82 |
| ≥ 0.15 µg/mL [1 year post-vaccination] (N=255,91) | 252 | 91 |
| ≥ 0.15 µg/mL [2 years post-vaccination] (N=237,84) | 235 | 84 |
| ≥ 0.15 µg/mL [3 years post-vaccination] (N=233,78) | 231 | 77 |
| ≥ 0.15 µg/mL [4 years post-vaccination] (N=204,73) | 202 | 73 |
| ≥ 1.0 µg/mL [Prior to vaccination] (N=285,98) | 77 | 22 |
| ≥ 1.0 µg/mL [1 month post-vaccination] (N=292,100) | 286 | 100 |
| ≥ 1.0 µg/mL [1 year post-vaccination] (N=255,91) | 209 | 80 |
| ≥ 1.0 µg/mL [2 years post-vaccination] (N=237,84) | 174 | 72 |
| ≥ 1.0 µg/mL [3 years post-vaccination] (N=233,78) | 164 | 64 |
| ≥ 1.0 µg/mL [4 years post-vaccination] (N=204,73) | 144 | 57 |
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| ≥ 0.15 µg/mL [5 years post-vaccination] | 191 | 67 |
| ≥ 1.0 µg/mL [5 years post-vaccination] | 129 | 47 |
Concentrations are given as Geometric Mean Concentrations (GMCs).
| microgram per milliliter (µg/mL) | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Prior to vaccination (N=285, 98) | 0.438 (0.374 to 0.512) | 0.472 (0.364 to 0.611) |
| 1 month after vaccination (N=292, 100) | 46.652 (38.929 to 55.907) | 73.976 (57.624 to 94.968) |
| 1 year after vaccination (N=255, 91) | 3.550 (2.988 to 4.218) | 4.802 (3.708 to 6.218) |
| 2 years after vaccination (N= 237, 84) | 2.5 (2.1 to 3.0) | 3.3 (2.5 to 4.2) |
| 3 years after vaccination (N= 233, 78) | 2.234 (1.886 to 2.647) | 2.751 (2.113 to 3.582) |
| 4 years after vaccination (N= 204, 73) | 2.116 (1.773 to 2.524) | 2.964 (2.215 to 3.966) |
Concentrations are given as Geometric Mean Concentrations (GMCs).
| microgram per milliliter (µg/mL) | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations | 2.131 (1.752 to 2.592) | 2.537 (1.815 to 3.546) |
Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| ≥ 0.3 µg/mL [prior to vaccination] (N=283, 96) | 2 | 1 |
| ≥ 0.3 µg/mL [1 month post-vaccination] (N=290,100) | 290 | 100 |
| ≥ 0.3 µg/mL [1 year post-vaccination] (N=250, 91) | 95 | 33 |
| ≥ 0.3 µg/mL [2 years post-vaccination] (N=233,84) | 47 | 17 |
| ≥ 0.3 µg/mL [3 years post-vaccination] (N=230,79) | 24 | 8 |
| ≥ 2.0 µg/mL [prior to vaccination] (N=283, 96) | 0 | 0 |
| ≥ 2.0 µg/mL [1 month post-vaccination] (N=290,100) | 289 | 96 |
| ≥ 2.0 µg/mL [1 year post-vaccination] (N=250, 91) | 6 | 0 |
| ≥ 2.0 µg/mL [2 years post-vaccination] (N=233,84) | 1 | 1 |
| ≥ 2.0 µg/mL [3 years post-vaccination] (N=230,79) | 1 | 1 |
Concentrations given as Geometric Mean Concentrations (GMCs).
| micrograms per milliliter (µg/mL) | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Prior to vaccination (N=283, 96) | NA (NA to NA) | NA (NA to NA) |
| 1 month after vaccination (N=290,100) | 18.69 (17.10 to 20.42) | 7.95 (6.95 to 9.08) |
| 1 year after vaccination (N=250, 91) | NA (NA to 0.30) | NA (NA to NA) |
| 2 years after vaccination (N= 233, 84) | 0.2 (NA to NA) | 0.2 (NA to NA) |
| 3 years after vaccination (N= 230, 79) | NA (NA to NA) | NA (NA to NA) |
Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Pain | 91 | 42 |
| Redness | 146 | 64 |
| Swelling | 78 | 41 |
| Drowsiness | 102 | 40 |
| Fever | 76 | 30 |
| Irritabily | 154 | 69 |
| Loss of appetite | 102 | 40 |
Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Number of Subjects Reporting Unsolicited Symptoms | 217 | 81 |
A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.
| Subjects | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| Vaccination Phase (N=324, 109) | 4 | 2 |
| Until year 5 (N=295, 100) | 0 | 0 |
Collected over Up to Year 5 for Serious Adverse Events. Within 31 days after vaccination for Other Adverse Events that were not systematically assessed. Within 4 days after vaccination for Other Adverse Events that were systematically assessed.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Menitorix Group | — | 4/324 (1.2%) | 293/324 (90.4%) |
| Meningitec + Hiberix Group | — | 2/109 (1.8%) | 104/109 (95.4%) |
| Event | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/324 | 1/109 |
| PneumoniaInfections and infestations | 0/324 | 1/109 |
| PyrexiaGeneral disorders | 0/324 | 1/109 |
| RashSkin and subcutaneous tissue disorders | 0/324 | 1/109 |
| Breath holdingPsychiatric disorders | 1/324 | 0/109 |
| ConvulsionNervous system disorders | 1/324 | 0/109 |
| Croup infectiousInfections and infestations | 1/324 | 0/109 |
| GastroenteritisInfections and infestations | 1/324 | 0/109 |
| Traumatic brain injuryInjury, poisoning and procedural complications | 1/324 | 0/109 |
| Event | Menitorix Group | Meningitec + Hiberix Group |
|---|---|---|
| IrritabilityGeneral disorders | 154/324 | 69/109 |
| RednessGeneral disorders | 146/324 | 64/109 |
| PainGeneral disorders | 91/324 | 42/109 |
| SwellingGeneral disorders | 78/324 | 41/109 |
| DrowsinessGeneral disorders | 102/324 | 40/109 |
| Loss of appetiteGeneral disorders | 102/324 | 40/109 |
| Fever (above or equal to 38 degrees Celsius)General disorders | 76/324 | 30/109 |
| Upper respiratory tract infectionInfections and infestations | 54/324 | 13/109 |
| RashSkin and subcutaneous tissue disorders | 24/324 | 17/109 |
| TeethingGastrointestinal disorders | 40/324 | 15/109 |
| Age, Continuous(Months) | Menitorix Group | Meningitec + Hiberix Group | Total |
|---|---|---|---|
| Mean | 12.5 ± 0.94 | 12.5 ± 0.75 | 12.5 ± 0.90 |
| Sex: Female, Male(Participants) | Menitorix Group | Meningitec + Hiberix Group | Total |
|---|---|---|---|
| Female | 150 | 42 | 192 |
| Male | 174 | 67 | 241 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2006, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.